BEAT

Rating neutralAI Memo

HeartBeam

As of 2026-09-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

ALIGN-ACS pilot results at TCT 2026 • 2026-10-31

Base target: $1 / p=45% prob

Biggest risk

The company remains pre-scale with a $5.0 million Q2 net loss, $8.8 million of cash and restricted cash at June 30, and no demonstrated material revenue base. Heart-attack detection is not yet an approved indication, while the new $25 million ATM facility adds dilution risk [#IR-2026-08-13] [#SEC-8K-2026-08-14].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

HeartBeam has FDA-cleared arrhythmia technology, completed ALIGN-ACS enrollment early, surpassed 50% HEADSTART-ACS enrollment, signed agreements in four U.S. geographies, and reduced projected 2026 operating cash outflow below $14 million [#IR-2026-08-13]. Successful clinical readouts and conversion of pilots into recurring orders could materially re-rate the stock.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-03

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ATM dilution and Nasdaq compliance overhang
Early commercial order ramp
12-lead extended-wear patch validation

BearKey bullets

Cash remains limited relative to operating losses; additional equity issuance and dilution are possible under the $25 million ATM agreement [#SEC-8K-2026-08-14].
Clinical, manufacturing, reimbursement, partner-conversion, and execution risks are elevated for this low-coverage micro-cap medtech issuer.
Commercial launch is early, with initial orders and patients but no proven revenue scale or repeat-order economics.

WatchKey bullets

ALIGN-ACS pilot results at TCT 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=45%)

Target spread vs base: +90% / -64%

Scenario probabilities

Bull Target: $1 (p=25%)Base Target: $1 (p=45%)Bear Target: $0 (p=30%)

Commentary

Recent issuer-driven coverage is constructive around clinical enrollment, commercial launch, prototype development, and lower cash burn. Social, options, short-interest, employee-review, and reliable analyst-revision data are unavailable; the constructive tone should therefore be treated as low-confidence monitoring context rather than confirmation of operating traction.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ATM dilution and Nasdaq compliance overhang
Early commercial order ramp
12-lead extended-wear patch validation

Scenarios

Bull Target (Scenario probability)

$1 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.68

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-31
ALIGN-ACS pilot results at TCT 2026
The company completed enrollment of 134 patients ahead of schedule and expects full results at TCT 2026 on October 31-November 3; results are intended to inform a U.S. pivotal study and potential FDA indication expansion [#IR-2026-08-13].
Prob 55.00% • Move 40.00% • Priced-in 30.00%
EVENT2026-12-31
FDA pathway and pivotal-study clarification
Management says it is engaged with the FDA on study design and indication-expansion pathways and expects additional timeline detail by year-end [#IR-2026-08-13].
Prob 45.00% • Move 30.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

ATM dilution and Nasdaq compliance overhang
2026-12-28
HeartBeam entered a new agreement allowing up to $25 million of common-stock sales through an ATM program, creating dilution risk [#SEC-8K-2026-08-14]. The prior Nasdaq bid-price deficiency remains a material delisting risk through December 28, 2026 [#SEC-8K-2026-07-02].
Prob 65% • Move -18% • Priced-in 70%

Long-term Catalysts

Months to a year

Early commercial order ramp
2026-09-30
HeartBeam reports signed agreements across four U.S. geographies, shipped initial orders, onboarded patients, and increasing order magnitude in Q3 2026. Revenue scale remains unproven [#IR-2026-08-13].
Prob 45% • Move 35% • Priced-in 35%
12-lead extended-wear patch validation
2026-12-31
The company completed a working prototype and began a roughly 50-patient pilot targeting ischemia and complex-arrhythmia monitoring; partnership and reimbursement execution remain unvalidated [#IR-2026-08-13].
Prob 35% • Move 45% • Priced-in 15%

Risks

Cash remains limited relative to operating losses; additional equity issuance and dilution are possible under the $25 million ATM agreement [#SEC-8K-2026-08-14].
Clinical, manufacturing, reimbursement, partner-conversion, and execution risks are elevated for this low-coverage micro-cap medtech issuer.
Commercial launch is early, with initial orders and patients but no proven revenue scale or repeat-order economics.
FDA indication expansion and pivotal-study timing remain uncertain; current cleared use is for arrhythmia assessment, not myocardial infarction or ischemia [#IR-2026-08-13].
Failure to regain Nasdaq's $1.00 minimum bid requirement by December 28, 2026 could lead to delisting proceedings [#SEC-8K-2026-07-02].

Peers

Symbol	Summary
ABT	Strategic-scale cardiac-monitoring benchmark; the extreme size gap highlights HeartBeam's limited validation, distribution, and reimbursement depth.
BSX	Large cardiac-device benchmark useful for framing commercialization and regulatory execution, but not a close valuation comparable.
CTSO	Small-cap same-sector reference; product comparability is limited, so it is mainly relevant for financing durability and adoption risk.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

ABT

Strategic-scale cardiac-monitoring benchmark; the extreme size gap highlights HeartBeam's limited validation, distribution, and reimbursement depth.

BSX

Large cardiac-device benchmark useful for framing commercialization and regulatory execution, but not a close valuation comparable.

CTSO

Small-cap same-sector reference; product comparability is limited, so it is mainly relevant for financing durability and adoption risk.